Cancer Treatment Reviews
Volume 30, Issue 6 , Pages 555-562 , October 2004

New approaches to prevent intestinal toxicity of irinotecan-based regimens

  • Andrea Alimonti

      Affiliations

    • Division of Medical Oncology, San Pietro Hospital, FBF International, Rome, Italy
    • Division of Medical Oncology A, Regina Elena Cancer Institute,Via Elio Chianesi 53 00144, Rome, Italy
    • These authors contributed equally to this work.
    • ,
  • Alain Gelibter

      Affiliations

    • Division of Medical Oncology A, Regina Elena Cancer Institute,Via Elio Chianesi 53 00144, Rome, Italy
    • Corresponding Author InformationCorresponding author. Tel.: +39-06-5266-6919; fax: +39-06-5266-5637
    • These authors contributed equally to this work.
    • ,
  • Ida Pavese

      Affiliations

    • Division of Medical Oncology, San Pietro Hospital, FBF International, Rome, Italy
    • ,
  • Francesco Satta

      Affiliations

    • Division of Medical Oncology, San Pietro Hospital, FBF International, Rome, Italy
    • ,
  • Francesco Cognetti

      Affiliations

    • Division of Medical Oncology A, Regina Elena Cancer Institute,Via Elio Chianesi 53 00144, Rome, Italy
    • ,
  • Gianluigi Ferretti

      Affiliations

    • Division of Medical Oncology A, Regina Elena Cancer Institute,Via Elio Chianesi 53 00144, Rome, Italy
    • ,
  • Debora Rasio

      Affiliations

    • Division of Medical Oncology, La Sapienza II Faculty of Medicine, Rome, Italy
    • ,
  • Aldo Vecchione

      Affiliations

    • Division of Medical Oncology, La Sapienza II Faculty of Medicine, Rome, Italy
    • ,
  • Mario Di Palma

      Affiliations

    • Division of Medical Oncology, San Pietro Hospital, FBF International, Rome, Italy

References 

  1. Cunningham D, Pyrohone S, James RD, et al.  Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 1998;352:1413–1418
  2. Rougier P, Van Cutsem E, Bajetta E, et al.  Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet. 1998;352:1407–1412
  3. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al.  Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med. 2000;343(13):905–914
  4. Rougier P, Bugat R, Douillard JY, et al.  Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J. Clin. Oncol. 1997;15:251–260
  5. Kudoh S, Fujiwara Y, Takada Y, Yamamoto H, Kinoshita A, Ariyoshi Y, et al.  Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group. J. Clin. Oncol. 1998;16:1068–1074
  6. Irvin WP, Price FV, Bailey H, Gelder M, Rosenbluth R, Durivage HJ, et al.  A Phase II study of irinotecan in patients with advanced squamous-cell carcinoma of the cervix. Cancer. 1998;82:328–333
  7. Sugiyama T, Yakushiji M, Nishida T, et al.  Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer. Cancer Lett. 1998;128:211–218
  8. Noda K, Nishiwaki Y, Kawahara M, et al.  Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N. Engl. J. Med. 2002;346:85–91
  9. Jagasia MH, Langer CJ, Johnson DH, et al.  Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study. Clin. Cancer. Res. 2001;7:68–73
  10. Rocha Lima C, Savarese D, Bruckner H, et al.  Multicenter phase II trial of first-line irinotecan and gemcitabine (irimogem) in patients with locally advanced or metastatic pancreatic cancer (PC). Proc. Am. Soc. Clin. Oncol. 2000;19:263a
  11. Hecht JR. Gastrointestinal toxicity of irinotecan. Oncology. 1998;12:72–78
  12. Sargent DJ, Niedzwiecki D, O'Connell MJ, Schilsky RL. Reccomendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N. Engl. J. Med. 2001;345:144–145
  13. Cunningham D, Maroun J, Vanhoefer U, Van Cutsem E. Optimizing the use of irinotecan in colorectal cancer. Oncologist. 2001;6(Suppl 4):17–23
  14. Liu LF, Desai SD, Li TK, et al.  Mechanism of action of camptothecin. Ann. N. Y. Acad. Sci. 2000;922:1–10
  15. Hsiang Y-H, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem. 1985;260(27):14873–14878
  16. Shao RG, Cao CX, Zhang H, et al.  Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA: DNA-PK complexes. EMBO J. 1999;18:1397–1406
  17. Rivory LP, Bowles R, Robert J, Pond SM. Conversion of irinotecan (CPT-11) to its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) by human liver carboxylesterase. Biochemical Pharmacology. 1996;52:1103–1111
  18. Sparreboom A, De Jonge MJ, De Bruijn P, Brouwer E, Nooter K, Loos WJ, et al.  Irinotecan Metabolism and Disposition in cancer patients. Clinical Cancer Research. 1998;4(November):2747–2754
  19. Kaneda N, Yokokura T, et al.  Nonlinear pharmacokinetics of CPT-11 in rats. Cancer Res. 1990;50:1721–1725
  20. Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ. Metabolic fate of irinotecan in humans correlation of glucuronidation with diarrhoea. Cancer Res. 1994;54(14):3723–3725
  21. Rivory LP, Haaz MC, Canal P, Lokiec F, Armand JP, Robert J. Pharmacokinetic interrelationship of Irinotecan and its three major plasma metabolites in patients enrolled in phase I/II trial. Clinical Cancer Research. 1997;3(August):1261–1266
  22. Rivory LP, Riou J-F, Haaz M-C, Sable S, Vuilhorgne M, Commerçon A, et al.  Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients. Cancer Res. 1996;56:3689–3694
  23. Xie R, Mathijssen RHJ, Sparreboom A, Verweij J, Karlsson MO. Clinical Pharmacokinetics of Irinotecan and Its Metabolites: A Population Analysis. J. Clin. Oncol. 2002;20(15):3293–3301
  24. Mathijssen RHJ, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, et al.  Clinical Pharmacokinetics and Metabolism of Irinotecan (CPT-11). Clin. Cancer Res. 2001;7(8):2182–2194
  25. Iyer L, King C, Hall D, et al.  Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin. Pharmacol. Ther. 1999;65:576–582
  26. Wasserman E, Myara A, Lokiec F, et al.  Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. Ann. Oncol. 1997;8:1049–1051
  27. Iyer L, King CD, Whitington PF, et al.  Genetic predisposition to the metabolism of irinotecan (CPT-11) Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J. Clin. Invest. 1998;101:847–854
  28. Kaneda N, Kurita A, Hosokawa Y, Yokokura T, Awazu S. Intravenous administration of Irinotecan elevates the blood Beta-Glucuronidase activity in rats. Cancer Research. 1997;57(December 1):5305–5308
  29. Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E, et al.  Involvement of β-Glucuronidase in Intestinal Microflora in the Intestinal Toxicity of the Antitumour Camptothecin Derivative Irinotecan Hydrochloride. Cancer Res. 1996;56(Aug. 15):3752–3757
  30. Takasuna K, Hagiwara T, Hirohashi M, Kato M, Nomura M, Nagai E, et al.  Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumour agent, irinotecan hydrochloride (CPT-11) in rats. Cancer Chemother. Pharmacol. 1998;42(4):280–286
  31. Kehrer DFS, Sparreboom A, Verweij J, De Bruijn P, Nierop CA, van de Schraaf J, et al.  Modulation of Irinotecan-induced Diahrrea by cotreatment with Neomycin in Cancer Patients. Clinical Cancer Research. 2001;7(May):1136–1141
  32. Ikegami T, Ha L, Arimori K, Latham P, Kobayashi K, Ceryak S, et al.  Intestinal alkalization as a possible preventive mechanism in irinotecan (CPT-11)-induced diarrhoea. Cancer Res. 2002;62(1):179–187
  33. Takeda Y, Kobayashi K, Akiyama Y, Soma T, Handa S, Kudoh S, et al.  Prevention of irinotecan (CPT-11)-induced diarrhoea by oral alkalization combined with control of defecation in cancer patients. Int. J. Cancer. 2001;92(2):269–275
  34. Gandia D, Abigerges D, Armand JP, Chabot GG, Da Costa L, De Forni M, et al.  CPT-11-induced cholinergic effects in cancer patients. J. Clin. Oncol. 1993;11:196–197
  35. Rougier P, Bugat R, Douillard JY, et al.  Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J. Clin. Oncol. 1997;15(1):251–260
  36. Von Hoff DD, Rothenberg ML, Pitot HC, et al.  Irinotecan (CPT-11) therapy for patients with previously treated metastatic colorectal cancer (CRC): overall results of FDA-reviewed pivotal US clinical trials. Proceedings of the American Society of Clinical Oncology. 1997;16:228a; abstract 803
  37. Saliba F, Hagipantelli R, Misset JL, et al.  Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhoea in patients with advanced colorectal cancer: a prospective assessment. Journal of Clinical Oncology. 1998;16(8):2745–2751
  38. Abigerges D, Armand JP, Chabot GG, Da Costa L, Fadel E, Cote C, et al.  Irinotecan high-dose escalation using intensive high-dose loperamide to control Diarrea. J. Natl. Cancer Inst. 1994;86:446–449
  39. Takasuna K, Kasai Y, Kitano Y, Mori K, Kobayashi R, Hagiwara T, et al.  Protective effects of kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats. Jpn. J. Cancer Res. 1995;86:978–984
  40. Lenfers BH, Loeffler TM, Droege CM, Hausamen TU. Substantial activity of budesonide in patients with irinotecan (CPT-11) and 5-fluorouracil induced diarrhoea and failure of loperamide treatment. Ann. Oncol. 1999;10:1251–1253
  41. Barbounis V, Koumakis G, Vassilomanolakis M, Demiri M, Efremidis AP. Control of irinotecan-induced diarrhoea by octreotide after loperamide failure. Support Care Cancer. 2001;9(4):258–260
  42. Pro B, Lozano R, Ajani JA. Therapeutic response to octreotide in patients with refractory CPT-11 induced diarrhoea. Invest New Drugs. 2001;19(4):341–343
  43. Ikuno N, Soda H, Watanabe M, et al.  Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum. J. Natl. Cancer Inst. 1995;87:1876–1883
  44. Guffroy M, Hodge T. Re: Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum (letter; comment). J. Natl. Cancer Inst. 1996;88:1240–1241
  45. Alimonti A, Satta F, Pavese I, Burattini E, Zoffoli V, Vecchione A. Prevention of irinotecan plus 5-fluorouracil/leucovorin-induced diarrhoea by oral administration of neomycin plus bacitracin in first-line treatment of advanced colorectal cancer. Ann. Oncol. 2003;14(5):805–806
  46. Alimonti A, Satta F, Pavese I, Todi F, Zoffoli MV, Di Palma M, et al.  Prevention of irinotecan (CPT-11) + 5-fluorouracil/leucovorin (FU/LV) diarrhoea by oral administration of neomycin + bacitracin in first line treatment of advanced colo-rectal cancer. Proc. Am. Soc. Clin. Oncol. 2003;22:278; abstr. 1116
  47. Sakata Y, Suzuki H, Kamataki T. Preventive effect of TJ-14, a kampo (Chinese herb) medicine, on diarrhoea induced by irinotecan hydrochloride (CPT-11). Gan. To Kagaku Ryoho. 1994;21(8):1241–1244
  48. Slatter J, Schaaf L, Sams J, et al.  Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following i.v. infusion of [14C]CPT-11 in cancer patients. Drug Metab. Dispos. 2000;28:423–433
  49. Kanna R, Morton C, Danks M, Potter P. Proficient metabolism of irinotecan by a human intestinal carboxylesterase. Cancer Res. 2000;60:4725–4728
  50. Kobayashi K, Bouscarel B, Matsuzaki Y, Ceryak S, Kudoh S, Fromm H. pH-dependent uptake of irinotecan and its active metabolite, SN-38, by intestinal cells. Int. J. Cancer. 1999;83(4):491–496
  51. Shinohara H, Killion JJ, Bucana CD, Yano S, Fidler IJ. Oral administration of the immunomodulator JBT-3002 induces endogenous interleukin 15 in intestinal macrophages for protection against irinotecan-mediated destruction of intestinal epithelium. Clin. Cancer Res. 1999;5(8):2148–2156
  52. Shinohara H, Killion JJ, Kuniyasu H, Kumar R, Fidler IJ. Prevention of intestinal toxic effects and intensification of irinotecan's therapeutic efficacy against murine colon cancer liver metastases by oral administration of the lipopeptide JBT 3002. Clin. Cancer Res. 1998;4(9):2053–2063
  53. Horikawa M, Kato Y, Sugiyama Y. Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats. Pharm. Res. 2002;19(9):1345–1353
  54. Kase Y, Hayakawa T, Togashi Y, Kamataki T. Relevance of inrinotecan hydrochloride-induced diarrhoea to the level of prostaglandin E2 and water absorption of large intestine in rats. Jpn. J. Pharmacol. 1997;75:399–405
  55. Sakai H, Sato T, Takahiro S, Hamada N, Yasue M, Ikari A, et al.  Thromboxane A2, released by the anti-tumour drug irinotecan, is a novel stimulator of Cl− secretion in isolated rat colon. J. Physiol. 1997;505:133–144
  56. Trifan OC, Durham WF, Salazar VS, Horton J, Levine BD, Zweifel BS, et al.  Cyclooxygenase-2 inhibition with celecoxib enhances antitumour efficacy and reduces diarrhoea side effect of CPT-11. Cancer Res. 2002;62(20):5778–5784
  57. Govindarajan R, Heaton KM, Broadwater R, Zeitlin A, Lang NP, Hauer-Jensen M. Effect of thalidomide on gastrointestinal toxic effects of irinotecan. Lancet. 2000;356(9229):566–567
  58. Chowbay B, Sharma A, Zhou QY, Cheung YB, Lee EJ. The modulation of irinotecan-induced diarrhoea and pharmacokinetics by three different classes of pharmacologic agents. Oncol. Rep. 2003;10(3):745–751
  59. Ratain MJ, Goh BC, Iyer L, et al.  A phase I study of irinotecan (CPT-11) with pharmacokinetic modulation by cyclosporine A (CSA) and phenobarbital (PB). Proc. Am. Soc. Clin. Oncol. 1999;18:202a; abstr. 777
  60. Fagbemi S, Iyer L, Mani S, et al.  Phase I and pharmacokinetic study of irinotecan (CPT-11) administered with cyclosporine (CSA). Proc. Am. Soc. Clin. Oncol. 1997;16:219a; abstr. 766
  61. Chester JD, Joel SP, Cheeseman SL, Hall GD, Braun MS, Perry J, et al.  Phase I and pharmacokinetic study of intravenous irinotecan plus oral ciclosporin in patients with fluorouracil-refractory metastatic colon cancer. Journal of Clinical Oncology. 2003;21(March 6):1125–1132
  62. Rothenberg ML, Hainsworth JD, Rosen L, et al.  Phase II study of irinotecan (CPT-11) 250 mg/m2 given every-other-week in previously treated colorectal cancer patients. Proc. Am. Soc. Clin. Oncol. 1998;17:284a; abstr. 1092
  63. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741
  64. Piccart-Gebhart MJ. Mathematics and oncology: a match for life?. J. Clin. Oncol. 2003;21(8):1425–1428

PII: S0305-7372(04)00096-9

doi: 10.1016/j.ctrv.2004.05.002

Cancer Treatment Reviews
Volume 30, Issue 6 , Pages 555-562 , October 2004

Article Tools